HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Intravitreal bevacizumab for juxtafoveal choroidal neovascularization secondary to multifocal choroiditis.

AbstractPURPOSE:
To assess the effects of intravitreal bevacizumab injections in the treatment of juxtafoveal choroidal neovascularization associated with multifocal choroiditis.
METHODS:
Prospective interventional case series. Fourteen patients (14 eyes) affected by juxtafoveal choroidal neovascularization secondary to multifocal choroiditis were examined. All patients underwent a complete ophthalmologic examination, including measurement of best-corrected visual acuity using Early Treatment Diabetic Retinopathy Study charts, optical coherence tomography, and fluorescein angiography. The protocol treatment included a first injection, followed by repeated intravitreal bevacizumab injections over a 12-month follow-up period on the basis of optical coherence tomography parameters and angiographic features.
RESULTS:
Mean best-corrected visual acuity changed from 0.41 logarithm of the minimum angle of resolution (approximately corresponding to 20/51 Snellen equivalent), at baseline, to 0.16 ± 0.13 logarithm of the minimum angle of resolution (approximately corresponding to 20/28 Snellen equivalent), at the 12-month examination (P < 0.002). A functional improvement of at least 3 Early Treatment Diabetic Retinopathy Study lines was achieved by 6 eyes (43%) at the 12-month examination. Mean central macular thickness at baseline was 318 μm, reducing to 239 μm at the 12-month examination (P < 0.001). No eye showed choroidal neovascularization extension to the fovea.
CONCLUSION:
Intravitreal bevacizumab is a beneficial treatment for juxtafoveal choroidal neovascularization associated with multifocal choroiditis. Further studies are warranted to confirm these preliminary results.
AuthorsMaurizio B Parodi, Pierluigi Iacono, Ahamad Mansour, Umberto de Benedetto, Karl A Knutsson, Francesco Bandello, Focke Ziemssen, Thomas Ness, David Dodwell
JournalRetina (Philadelphia, Pa.) (Retina) Vol. 33 Issue 5 Pg. 953-6 (May 2013) ISSN: 1539-2864 [Electronic] United States
PMID23503338 (Publication Type: Journal Article, Multicenter Study)
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
Topics
  • Adult
  • Angiogenesis Inhibitors (administration & dosage)
  • Antibodies, Monoclonal, Humanized (administration & dosage)
  • Bevacizumab
  • Choroidal Neovascularization (drug therapy, etiology, physiopathology)
  • Choroiditis (complications, physiopathology)
  • Female
  • Humans
  • Intravitreal Injections
  • Male
  • Middle Aged
  • Prospective Studies
  • Visual Acuity (physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: